Sort
11,323 grants matching “glioblastoma”
DNA Damage: Roles in Toxicity and Mutagenicity
$269,905Barry I Gold · University Of Pittsburgh At Pittsburgh · R01 · FY2008 · CA
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)
$269,745Duane A. Mitchell · University Of Florida · R01 · FY2020 · CA
Focal ultrasound-mediated nonthermal ablation of brain tumors
$269,662Tyrone Porter · Boston University (Charles River Campus) · R21 · FY2019 · EB
Biospecimen Acquisition, Processing, and Classification Unit
$269,658Ryan C Fields · Washington University · U2C · FY2018 · CA
Leveraging doxorubicin immune-modulation, blood-brain barrier opening, and personalized medicine for effective immunotherapy in glioblastoma. A mechanistic approach and pharmacokinetic trial.
$269,642Adam M Sonabend · University Of California, San Francisco · U19 · FY2025 · CA
Genetically engineered mouse models
$269,306Alain Charest · Massachusetts General Hospital · P01 · FY2016 · CA
MULTI-TARGETED RNAI THERAPEUTICS FOR GLIOBLASTOMA MULTIFORME (GBM)
$269,298Patrick Y Lu · Sirnaomics, Inc. · R43 · FY2010 · CA
FAK and Pky2 in Determination of Glioblstoma Phenotype
$269,087Joseph C Loftus · Mayo Clinic Arizona · R01 · FY2006 · CA
Retroviral replicating vector for prodrug activator gene therapy
$269,025Douglas J. Jolly · Tocagen, Inc. · R43 · FY2012 · CA
A randomized controlled phase 2 study of the ketogenic diet for patients with newly diagnosed glioblastoma in combination with standard-of-care treatment
$268,951Jethro Hu · Cedars-Sinai Medical Center · R01 · FY2025 · CA
Retrotransposon instability in glioblastoma multiforme
$268,920Jef D Boeke · Johns Hopkins University · R01 · FY2012 · CA
Retrotransposon instability in glioblastoma multiforme
$268,920Jef D Boeke · Johns Hopkins University · R01 · FY2011 · CA
TGFbeta-PTEN Interactions in Glioma Biology & Therapy
$268,871Jeremy N Rich · Duke University · R01 · FY2007 · CA
Project 2: Integrative Genomics of Cancer Survival
$268,746Yen-Tsung Huang · Brown University · P20 · FY2016 · GM
Novel Approaches for Pancreatic Cancer Therapy
$268,720Paul B Fisher · Columbia University Health Sciences · R01 · FY2007 · CA
Administrative Core
$268,582Tracy T Batchelor · Massachusetts General Hospital · P50 · FY2017 · CA
DNA Repair-Mediated BCNU Resistance in CNS Tumors
$268,417Henry S. Friedman · Duke University · P50 · FY2007 · NS
NMDA receptor function by serine protease receptors
$268,383Stephen F. Traynelis · Emory University · R01 · FY2007 · NS
Vascular targeted pan PI-3 kinase inhibitor prodrug, SF1126 for glioma therapy
$268,308Donald Durden Durden · University Of California, San Diego · R01 · FY2012 · CA
Vascular targeted pan PI-3 kinase inhibitor prodrug, SF1126 for glioma therapy
$268,308Donald Durden Durden · University Of California, San Diego · R01 · FY2011 · CA
RECONSTITUTION OF HEDGEHOG SIGNALING COMPLEX
$268,270University Of Cincinnati · R01 · FY2000 · CA
Treatment Planning using Physiologic MRI Data
$268,227M Elizabeth Meyerand · University Of Wisconsin-Madison · R01 · FY2008 · CA
Targeting MELK-mediated EZH2 signaling in glioma stem cells
$268,082Ichiro Nakano · Ohio State University · R01 · FY2013 · NS
Biospecimen Acquisition, Processing, and Classification Unit
$267,970Ryan C Fields · Washington University · U2C · FY2021 · CA
Continuous Probing of Nanoconstruct-Cell Interactions at Biologically Relevant Time Scales
$267,708Teri Wang Odom · Northwestern University · R01 · FY2019 · GM